Valuation: Beacon Pharmaceuticals PLC

Market Cap 25.48B 206M 178M 167M 153M 288M 19.58B 292M 1.95B 767M 9.78B 772M 755M 32.56B P/E 2024
68.2x
P/E 2025 25.8x
Enterprise Value 35.44B 286M 248M 232M 212M 401M 27.23B 406M 2.72B 1.07B 13.61B 1.07B 1.05B 45.29B EV / Sales 2024
4.25x
EV / Sales 2025 2.74x
Free-Float
36.94%
Yield 2024
1.3%
Yield 2025 1.98%
1 day-0.83%
1 week-0.74%
Current month-0.74%
1 month-5.77%
3 months+3.26%
6 months+3.06%
Current year+2.96%
1 week 107.4
Extreme 107.4
110.2
1 month 107
Extreme 107
117
Current year 96
Extreme 96
117.9
1 year 96
Extreme 96
147.5
3 years 92.4
Extreme 92.4
288.9
5 years 92.4
Extreme 92.4
393
10 years 16
Extreme 16
393
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - -
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 67 -
Director/Board Member 42 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-0.83%-0.74%-4.52%-56.04% 201M
+1.89%+3.20%+59.70%+165.18% 1,062B
-0.24%+0.45%+50.64%+52.02% 619B
-0.95%-5.26%+24.23%+65.08% 431B
0.00%+3.20%+46.70%+37.60% 358B
+0.58%-1.26%+35.52%+40.54% 293B
-1.55%-6.84%+7.20%+8.62% 247B
-0.73%+4.44%+42.22%+66.41% 219B
-0.24%-11.27%+1.42%-44.69% 200B
-0.68%-0.32%+18.66%+66.32% 162B
Average -0.55%-1.78%+28.18%+40.10% 359.25B
Weighted average by Cap. -0.54%-0.83%+40.83%+77.82%

Financials

2024 2025
Net sales 10.7B 86.32M 74.91M 70.14M 64.16M 121M 8.22B 123M 821M 322M 4.11B 324M 317M 13.67B 12.54B 101M 87.79M 82.21M 75.2M 142M 9.64B 144M 962M 377M 4.81B 380M 372M 16.03B
Net income 521M 4.2M 3.65M 3.41M 3.12M 5.9M 400M 5.97M 39.95M 15.68M 200M 15.78M 15.44M 666M 947M 7.63M 6.63M 6.2M 5.67M 10.71M 727M 10.85M 72.58M 28.48M 363M 28.66M 28.04M 1.21B
Net Debt 10B 80.63M 69.97M 65.52M 59.94M 113M 7.68B 115M 767M 301M 3.84B 303M 296M 12.77B 9.96B 80.36M 69.74M 65.3M 59.74M 113M 7.66B 114M 764M 300M 3.82B 302M 295M 12.73B
Logo Beacon Pharmaceuticals PLC
Beacon Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical finished formulation products and lifesaving Intravenous (I.V) fluids, active pharmaceuticals ingredients, biotech products, and genetic engineering products which it sells in the local markets as well as the international markets. The Company also provides contract and toll manufacturing services. Its products are focused on various drugs, such as anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, muscle relaxant, antihistamine, analgesics, and non-steroidal anti-inflammatory drugs (NSAIDS), among others. The Company's product categories include general, oncology, anti-viral, and biotech. Its products include Tagrix 80, Afanix 40, Ibrutix, Lenvanix 4, Palbonix, Crizonix, Sunitix, Wedica, Tafecta, Hernix, Obetix, Ribotix, among others.
Employees
4,771
Date Price Change Volume
06/08/26 BDT 107.70 -0.83% 122,825
04/08/26 BDT 108.60 0.00% 183,925
03/08/26 BDT 108.60 +0.09% 155,831
02/08/26 BDT 108.50 0.00% 106,204
30/07/26 BDT 108.50 +0.28% 197,132
  1. Stock Market
  2. Stocks
  3. BEACONPHAR Stock